• Open Daily: 10am - 10pm
    Alley-side Pickup: 10am - 7pm

    3038 Hennepin Ave Minneapolis, MN
    612-822-4611

Open Daily: 10am - 10pm | Alley-side Pickup: 10am - 7pm
3038 Hennepin Ave Minneapolis, MN
612-822-4611
Contraceptive Risk: The Fda, Depo-Provera, and the Politics of Experimental Medicine

Contraceptive Risk: The Fda, Depo-Provera, and the Politics of Experimental Medicine

Hardcover

Series: Biopolitics, Book 12

Medical ReferenceGeneral LawGeneral Political Science

ISBN10: 1479876992
ISBN13: 9781479876990
Publisher: New York Univ Pr
Published: May 2 2017
Pages: 336
Weight: 1.40
Height: 0.88 Width: 6.00 Depth: 9.00
Language: English

The story of Depo-Provera joins the national struggle over the drug's FDA approval to the state legal issues raised by its contraceptive and criminal justice uses.

Depo-Provera is known as an injectable hormonal birth control method, but few are familiar with its dark and complicated history. Depo-Provera was tested on women since the mid-1960s without their informed consent until it was FDA-approved in 1992, but never FDA-approved as chemical castration for male sex offenders.

Contraceptive Risk is William Green's landmark study of Depo-Provera. Based on a fascinating combination of archival materials and interviews, the book is framed as three interconnected stories told by Judith Weisz, who chaired the FDA's Public Board of Inquiry on Depo-Provera, a scientific court; by Anne MacMurdo who brought a products liability suit against Upjohn, the drug's manufacturer, for the deleterious side effects she suffered from the drug's use; and by Roger Gauntlett, an Upjohn heir who, when he was convicted of sexual assault, refused to take a dose of his family's own medicine as a probation condition. Together these three stories of Depo-Provera's convoluted fifty year odyssey call for a paradigm shift in pharmaceutical drug development.

1 different editions

Also available

Also in

General Political Science